These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25010857)

  • 1. Prolonged bradycardia and hypotension following guanfacine extended release overdose.
    Walton J; Byrum M; Shumaker A; Coury DL
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):463-5. PubMed ID: 25010857
    [No Abstract]   [Full Text] [Related]  

  • 2. A somnolent 2-year-old boy with a hyperactive brother.
    Fontane E; Shiber J
    Pediatr Emerg Care; 2013 Sep; 29(9):1033-6. PubMed ID: 24201989
    [No Abstract]   [Full Text] [Related]  

  • 3. Two case reports of extended-release guanfacine overdose in children.
    Shimozato A; Ohashi K; Saitoh S
    Pediatr Int; 2023 Jan; 65(1):e15424. PubMed ID: 36412228
    [No Abstract]   [Full Text] [Related]  

  • 4. Guanfacine extended-release (intuniv) for ADHD.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of excessive weight gain with guanfacine extended release: 9.53 kg in 4 weeks.
    Khan MA; Jain G; Soltys SM; Takahashi A
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):256-7. PubMed ID: 22537187
    [No Abstract]   [Full Text] [Related]  

  • 6. Guanfacine toxic ingestion with subsequent cardiogenic pulmonary edema.
    Bridwell RE; Larson NP; Rosenthal JB; Wray J; Baker Z; Cibrario A; Oliver JJ
    Am J Emerg Med; 2021 Jan; 39():256.e5-256.e8. PubMed ID: 33069545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
    Sallee FR; Eaton K
    Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System.
    Wang GS; Le Lait MC; Heard K
    J Pediatr; 2014 Jan; 164(1):149-52. PubMed ID: 24094880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment with guanfacine extended release and blonanserin for Tourette's syndrome comorbid with attention deficit hyperactivity disorder.
    Kawabe K; Horiuchi F; Ueno SI
    Psychiatry Clin Neurosci; 2019 Dec; 73(12):762-763. PubMed ID: 31588606
    [No Abstract]   [Full Text] [Related]  

  • 13. QT-Interval Prolongation Associated with Supratherapeutic Guanfacine Concentration: A Case Report.
    Inoue F; Okazaki Y; Kashiwa K; Ichiba T; Namera A
    J Med Toxicol; 2024 Apr; 20(2):218-221. PubMed ID: 38231419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanfacine extended release in two patients with pervasive developmental disorders.
    Blankenship K; Erickson CA; Stigler KA; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):287-90. PubMed ID: 21663433
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overdose of extended-release guanfacine.
    Fein DM; Hafeez ZF; Cavagnaro C
    Pediatr Emerg Care; 2013 Aug; 29(8):929-31. PubMed ID: 23925253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.